Drug Profile
Landipirdine - Acorda Therapeutics
Alternative Names: RO-5025181; RO5025181-000; SYN-120Latest Information Update: 09 Mar 2020
Price :
$50
*
At a glance
- Originator Roche
- Developer Acorda Therapeutics; Biotie Therapies Corp.
- Class Antidementias; Nootropics; Small molecules
- Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cognition disorders; Dementia